Navigation Links
Children with cystic fibrosis not well covered by guidelines for vitamin D needs
Date:10/9/2008

igators say, doctors caring for patients with CF should think about increasing the vitamin D intake beyond the current recommendations in those who are vitamin D deficient. They should also check vitamin D levels at least once a year in all CF patients and more frequently in those with abnormally low levels.

In the current study of CF patients treated at Hopkins Children's between 2003 and 2006, investigators found that 86 percent were vitamin D deficient in 2003, 50 percent were deficient in 2004, 54 percent were deficient in 2005, and 46 percent were deficient in 2006.

Comparing different weekly intakes of ergocalciferol, the Hopkins team found that the currently recommended 50,000 IU per week for eight weeks was effective in only 33 percent of the patients with vitamin D deficiency, while increasing the therapy to twice a week was effective in 26 percent of patients. Delivering the same dose three times a week corrected the deficiency in just 43 percent of children. Vitamin D levels appeared to follow fluctuations in seasonal sun exposure, dropping sharply in the fall and winter and peaking during spring and summer.

Vitamin D deficiency was worst during the fall, with 83 percent of patients testing deficient, while only 41 percent were vitamin D deficient in the summer. Sun exposure is critical for vitamin D synthesis and production. Some doctors recommend sun exposure twice a week for up to 30 minutes at a time, but the debate is ongoing because sun exposure without protection increases the risk of skin cancer.

"Clearly we haven't established an optimal dose for treating vitamin D deficiency and more research is needed to do so," says senior researcher Peter Mogayzel, M.D. Ph.D., director of Hopkins Children's Cystic Fibrosis Center. "But what we know for sure is that the current recommendations are too low, and doctors should treat their patients with vitamin D deficiencies more aggressively,"

New therapies and ear
'/>"/>

Contact: Katerina Pesheva
epeshev1@jhmi.edu
410-516-4996
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Children of depressed moms do better when dad is involved, SLU researcher finds
2. High pollution linked to poor lung function growth in children in Mexico City
3. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
4. Obese Children Miss More School Days
5. Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease
6. Psoriasis Cure Now offers Back to School Resources for Parents of Children with Psoriasis
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Practice-based intervention has sustained benefits for children and families
10. 1.5 million children could be saved
11. Annual flu shot cuts need for doctors visits, hospitalization among children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 As concerns about the ... morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) in gynecological surgeries mount, ... the continued use of uterine morcellation by some ... discouraged these procedures. According to The Wall Street ... risks associated with power morcellators are overblown, and ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... new AS365 N3+ Dauphin, the latest version of Airbus ... is based at Miami Valley Hospital in ... medical transport helicopters. , “We have a lot of ... Vice President, Emergency, Trauma, and CareFlight. “We’ve been operating ...
(Date:9/22/2014)... 2014 PCI (Project Concern International) ... equip women around the world with tools and training ... Women Empowered (WE) Initiative announced at the CGI Annual ... to pool their savings, invest in their own businesses, ... to ending poverty in the world, and through our ...
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 The ... the Department of Surgery at the Icahn School of ... Doctors New York Group for Plastic Surgery gives residents ... access to a team of world-renowned plastic surgeons performing ... C. Andrew Salzberg, MD, who led NYGPS, was named ...
(Date:9/22/2014)... WHO: LiveOps, Inc., the global ... solutions. , WHAT: The 10th annual Customer Response ... for the connected consumer. Constant change in technology ... challenges and opportunities for customer experience executives. The ... practices, network and learn from fellow attendees, speakers ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 2Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 3Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... CLARA, Calif., January 8 Align Technology,Inc. (Nasdaq: ... that the,Company will report fourth quarter and fiscal year ... close of market. Financial results will,be released over PR ... the,Investor Relations section of the Company,s website at, http://investor.aligntech.com ...
... TEAC America, Inc. launches its,next generation P-55C dye-sublimation ... available, during the CES Show at,the Las Vegas Convention ... The P-55C printer can be integrated with 3 TEAC ... With TEAC,s,AL220S and AL550S, customers can print up to ...
... Vyvanse as the Clinical Gold Standard, According to ... 8 Decision Resources, one of the world,s ... and healthcare issues, finds that physicians indicate there ... effective nonstimulant therapy approved for adult attention-deficit/hyperactivity disorder ...
... (Nasdaq: GHDX ) today announced the appointment ... president and chief operating officer,Popovits is now the president ... Cole has been appointed as chief operating officer and ... reporting to Popovits. , "Kim,s ...
... and FirstDoc (Documentum) Solutions Deliver Regulatory Document Management ... CSC (NYSE: CSC ) announced today ... content management (ECM) solutions, adding features designed to ... the document life cycle and the growing collaboration ...
... will force hospitals to reconsider or defer purchases ... GroupWALTHAM, Mass., Jan. 8 According to Millennium ... RIS, and CVIS 2009 report, the budgetary ... affect the markets for picture archiving and communication ...
Cached Medicine News:Health News:Align Technology to Announce Fourth Quarter and Fiscal Year 2008 Results on January 28, 2009 2Health News:TEAC America Launches its Next Generation P-55C Printer, World's Fastest Dye-Sublimation Disc Printer 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 3Health News:Genomic Health Announces Management Changes and New Responsibilities 2Health News:Genomic Health Announces Management Changes and New Responsibilities 3Health News:Genomic Health Announces Management Changes and New Responsibilities 4Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 2Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 3Health News:Budgetary Constraints on Health Care Facilities to Affect PACS, RIS, and CVIS Markets 2
(Date:9/22/2014)... WASHINGTON , Sept. 22, 2014 ... deadline of Monday, Sept. 29 at 5 p.m. ... for Kids!" competition, in response to continued strong ... of $50,000 each will be awarded to the ... Pediatric Surgical Innovation Symposium hosted by Children,s National ...
(Date:9/22/2014)... 22, 2014  Elusys Therapeutics, Inc. (Elusys), a ... disease, today announced it has completed three phase ... (ETI-204). Obiltoxaximab is an anti-toxin in development for ... these studies support the safety and tolerability of ... intended therapeutic dose. The conclusion of these studies ...
(Date:9/22/2014)... , Sept. 22, 2014  Continua and ... in healthcare technology, media and telecommunications,  have formed ... China and promote international ... BHG announced this new partnership during the global ... Washington, DC , while also ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4
... There are some two dozen oncology therapies in Phase ... development. While only some of these therapies will make it ... a competitive marketplace where success revolves around planning as much ... in the oncology therapeutic area must constantly evaluate which factors ...
... April 20, 2012 A recent clinical trial conducted at ... drug used to treat Parkinson,s Disease greatly improves the quality ... such as tremors, slowness, stiffness and difficulty walking. ... hold the trial, which was led by Dr. C. Warren ...
Cached Medicine Technology:Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector 2Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease 2Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: